Nature Communications (Nov 2018)
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
- A. N. Niemeijer,
- D. Leung,
- M. C. Huisman,
- I. Bahce,
- O. S. Hoekstra,
- G. A. M. S. van Dongen,
- R. Boellaard,
- S. Du,
- W. Hayes,
- R. Smith,
- A. D. Windhorst,
- N. H. Hendrikse,
- A. Poot,
- D. J. Vugts,
- E. Thunnissen,
- P. Morin,
- D. Lipovsek,
- D. J. Donnelly,
- S. J. Bonacorsi,
- L. M. Velasquez,
- T. D. de Gruijl,
- E. F. Smit,
- A. J. de Langen
Affiliations
- A. N. Niemeijer
- Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- D. Leung
- Bristol-Myers Squibb Research and Development
- M. C. Huisman
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- I. Bahce
- Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- O. S. Hoekstra
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- G. A. M. S. van Dongen
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- R. Boellaard
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- S. Du
- Bristol-Myers Squibb Research and Development
- W. Hayes
- Bristol-Myers Squibb Research and Development
- R. Smith
- Bristol-Myers Squibb Research and Development
- A. D. Windhorst
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- N. H. Hendrikse
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- A. Poot
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- D. J. Vugts
- Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- E. Thunnissen
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- P. Morin
- Bristol-Myers Squibb Research and Development
- D. Lipovsek
- Bristol-Myers Squibb Research and Development
- D. J. Donnelly
- Bristol-Myers Squibb Research and Development
- S. J. Bonacorsi
- Bristol-Myers Squibb Research and Development
- L. M. Velasquez
- Bristol-Myers Squibb Research and Development
- T. D. de Gruijl
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- E. F. Smit
- Department of Thoracic Oncology, Netherlands Cancer Institute
- A. J. de Langen
- Department of Pulmonary Diseases, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam
- DOI
- https://doi.org/10.1038/s41467-018-07131-y
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 5
Abstract
Assessment of PD-1 and PD-L1 expression can be predictive of immunotherapy response in lung cancer. Here the authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lung cancer prior to treatment with immunotherapy and show it correlates with response.
